Sean Black, co-founder and CEO of Knock, talks about his announcement to take the company public in 2020. Knock allows homeowners to sell or trade in their home for a better one. Black says the company decided to announce its IPO plans two years in advance thanks to his affinity for the NYSE. The NYSE also reserved Knock's ticker symbol: KNCK. Black says the difference between Knock and a competitor like OpenDoor is that Knock will help homeowners purchase their next home, while OpenDoor will not. Black says OpenDoor also charges fees on top of the usual 3% for brokers.

Share:
More In Business
Hard pass, Cold brew, Dad bod: Merriam-Webster adds 5,000 new words
Merriam-Webster has fully revised its popular “Collegiate” dictionary with over 5,000 new words. They include “petrichor,” “dumbphone” and “ghost kitchen.” Also “cold brew,” “rizz,” “dad bod,” “hard pass,” “cancel culture” and more.
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More